v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows used in operating activities:    
Net loss $ (84,707) $ (77,350)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 14,438 14,183
Depreciation expense 141 297
Accretion of investment discounts, net (1,826) (3,226)
Charge for in-process research and development ("IPR&D") milestones 4,000  
Other non-cash items 84 264
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 1,108 6,941
Operating lease right-of-use assets 640 1,099
Deposits and other assets (2) 24
Accounts payable 2,014 338
Accrued expenses (3,494) (6,484)
Operating lease liabilities (702) (1,158)
Net cash used in operating activities (68,306) (65,072)
Cash flows used in investing activities:    
Purchases of property and equipment (30) (28)
Milestone payments related to IPR&D (4,000)  
Purchases of investments (200,505) (142,637)
Proceeds from maturities of marketable securities 91,000 122,000
Net cash used in investing activities (113,535) (20,665)
Cash flows provided by financing activities:    
Proceeds from financings, net of issuance costs   65,577
Proceeds from exercise of stock options and RSUs vesting 9,132 1,042
Withholding taxes paid on stock-based awards (4,436) (988)
Net cash provided by financing activities 4,696 65,631
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents (179) 805
Net decrease in cash, cash equivalents and restricted cash equivalents (177,324) (19,301)
Cash, cash equivalents and restricted cash equivalents, beginning of period 227,636 78,837
Cash, cash equivalents and restricted cash equivalents, end of period 50,312 59,536
Reconciliation of cash, cash equivalents and restricted cash equivalents:    
Cash and cash equivalents 49,326 58,085
Restricted cash equivalents 986 1,451
Total cash, cash equivalents and restricted cash equivalents: $ 50,312 $ 59,536